
51 - 200 employees
Founded 2004
🧬 Biotechnology
💊 Pharmaceuticals
💰 $75M Post IPO equity on 2024-02
Biotechnology • Pharmaceuticals
Liquidia is a biopharmaceutical company focused on developing inhaled therapies for rare cardiopulmonary diseases, particularly pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD). The company leverages its proprietary PRINT® particle engineering technology to create proprietary formulations and delivery methods aimed at improving efficacy, tolerability, and convenience of inhaled medicines; its pipeline includes inhaled treprostinil (commercial product) and clinical-stage candidates such as L606. Liquidia emphasizes patient support, clinical development, and advancing therapies for improved respiratory outcomes.
Selected: 🆕 Date Added.
🕒 4 days ago
Associate Director serving as reimbursement expert for Liquidia’s patient access programs. Improving referrals, coverage, adherence, and payer access for specialty pharmaceutical products.
🇺🇸 United States – Remote
💰 $75M Post IPO equity on 2024-02
⏰ Full Time
🟠 Senior
👔 Director
👻 Ghost score 10%
🕒 4 days ago
Associate Director guiding payer access, reimbursement, and referral pull-through for Liquidia’s specialty pharmaceutical products. Supporting HCPs, accounts, and internal teams across the Gulf Coast and Southeast.
🇺🇸 United States – Remote
💰 $75M Post IPO equity on 2024-02
⏰ Full Time
🟠 Senior
👔 Director
👻 Ghost score 10%
🕒 5 days ago
Regional Business Director leading PAH therapy sales teams and launching Yutrepia for Liquidia. Driving regional strategy, stakeholder relationships, coaching, and compliant commercial execution.
🇺🇸 United States – Remote
💰 $75M Post IPO equity on 2024-02
⏰ Full Time
🔴 Lead
👔 Director
👻 Ghost score 10%
🕒 October 15
Legal Operations Manager optimizing legal technology, contracts, budgets, and compliance for Liquidia, a biopharmaceutical company developing pulmonary hypertension therapies.
🇺🇸 United States – Remote
💰 $75M Post IPO equity on 2024-02
⏰ Full Time
🟠 Senior
🔴 Lead
🧑💼 Attorney / Lawyer
👻 Ghost score 10%
🕒 October 15
Senior Manager guiding global regulatory strategy and submissions for Liquidia’s pulmonary hypertension drug-device therapies. Coordinating clinical development, commercialization, and global health-authority interactions.
🇺🇸 United States – Remote
💰 $75M Post IPO equity on 2024-02
⏰ Full Time
🟠 Senior
🚔 Compliance
👻 Ghost score 10%
🕒 October 14
Financial compliance associate auditing HCP spend and transparency reporting for Liquidia, a life sciences company developing pulmonary arterial hypertension therapies.
🇺🇸 United States – Remote
💰 $75M Post IPO equity on 2024-02
⏰ Full Time
🟡 Mid-level
💸 Financial Planning and Analysis (FP&A)
👻 Ghost score 10%
🕒 October 14
Clinical Nurse Educator supporting pulmonary hypertension care teams with YUTREPIA administration and inhalation education. Delivering field-based training, coordinating resources, and sharing insights with Liquidia Medical Affairs.
🇺🇸 United States – Remote
💰 $75M Post IPO equity on 2024-02
⏰ Full Time
🟡 Mid-level
🟠 Senior
👻 Ghost score 10%
🕒 October 14
Clinical Nurse Educator supporting Liquidia’s YUTREPIA pulmonary hypertension therapy education. Training healthcare teams, strengthening inhalation competency, and sharing field insights with Medical Affairs.
🇺🇸 United States – Remote
💰 $75M Post IPO equity on 2024-02
⏰ Full Time
🟡 Mid-level
🟠 Senior
👻 Ghost score 10%
🕒 October 14
Clinical Nurse Educator educating U.S. pulmonary hypertension care teams on Liquidia's YUTREPIA therapy. Supporting inhalation competency, clinical workflows, field insights, and Medical Affairs compliance.
🇺🇸 United States – Remote
💰 $75M Post IPO equity on 2024-02
⏰ Full Time
🟡 Mid-level
🟠 Senior
👻 Ghost score 10%
🕒 October 14
Clinical Nurse Educator supporting pulmonary hypertension care teams and YUTREPIA inhalation education for Liquidia. Delivering clinical training, coordinating resources, and capturing field insights.
🇺🇸 United States – Remote
💰 $75M Post IPO equity on 2024-02
⏰ Full Time
🟡 Mid-level
🟠 Senior
👻 Ghost score 10%
🕒 October 13
Trade and distribution manager overseeing pharmaceutical order management, compliance, and 3PL performance at Liquidia. Supporting launches, cold-chain operations, data feeds, and distribution improvements.
🇺🇸 United States – Remote
💰 $75M Post IPO equity on 2024-02
⏰ Full Time
🟡 Mid-level
🟠 Senior
👔 Manager
👻 Ghost score 10%
🕒 October 11
Clinical product training manager delivering disease-state, product, and device education for Liquidia’s pulmonary hypertension therapies. Supporting specialty pharmacy partners, patient access, compliance, and field teams across the Northeast.
🇺🇸 United States – Remote
💰 $75M Post IPO equity on 2024-02
⏰ Full Time
🟠 Senior
🔴 Lead
👔 Manager
👻 Ghost score 10%
🕒 October 10
Patient support programs director advancing access and affordability for Liquidia’s pulmonary hypertension therapies. Leading HUB vendors, reimbursement, adherence, and compliance programs.
🇺🇸 United States – Remote
💰 $75M Post IPO equity on 2024-02
⏰ Full Time
🟠 Senior
👔 Director
👻 Ghost score 10%
🕒 October 1
Associate Director managing global clinical supply planning, forecasting, vendors, and regulatory compliance for Liquidia’s pulmonary hypertension therapies. Ensuring uninterrupted trial material availability worldwide.
🇺🇸 United States – Remote
💰 $75M Post IPO equity on 2024-02
⏰ Full Time
🟠 Senior
👨⚕️ Medical Director
👻 Ghost score 10%
🕒 October 1
Clinical Study Manager leading pharmaceutical clinical studies for Liquidia’s pulmonary hypertension therapies. Managing vendors, protocols, budgets, sites, data, and regulatory compliance.
🌲 North Carolina – Remote
💰 $75M Post IPO equity on 2024-02
⏰ Full Time
🟡 Mid-level
🟠 Senior
🧪 Clinical Research
👻 Ghost score 10%
🕒 September 30
Sales Area Director leading Liquidia’s pulmonary hypertension pharmaceutical sales organization. Managing regional sales leaders, KOL relationships, forecasting, and growth for Yutrepia and Treprostinil Injection.
🕒 September 30
Medical Information Manager supporting Liquidia’s pulmonary hypertension therapies. Developing evidence-based responses, managing medical resources, and reviewing scientific and promotional materials.
🌲 North Carolina – Remote
💰 $75M Post IPO equity on 2024-02
⏰ Full Time
🟡 Mid-level
🟠 Senior
👔 Manager
👻 Ghost score 10%
🕒 September 12
Executive Director leading clinical pharmacokinetics and pharmacometrics strategy for Liquidia’s pulmonary hypertension therapies. Guiding studies, modeling, regulatory submissions, and cross-functional drug development.
🇺🇸 United States – Remote
💰 $75M Post IPO equity on 2024-02
⏰ Full Time
🔴 Lead
👨⚕️ Medical Director
👻 Ghost score 18%
🕒 July 27
Sales professional managing territory accounts focusing on pulmonary hypertension treatments for Liquidia. Leveraging entrepreneurial mindset to grow sales within specific geographic areas.
🗽 New York – Remote
💰 $75M Post IPO equity on 2024-02
⏰ Full Time
🟡 Mid-level
🟠 Senior
💰 Account Manager
👻 Ghost score 40%